GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » ROE %

KORU Medical Systems (KORU Medical Systems) ROE % : -39.24% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. KORU Medical Systems's annualized net income for the quarter that ended in Mar. 2024 was $-7.74 Mil. KORU Medical Systems's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $19.74 Mil. Therefore, KORU Medical Systems's annualized ROE % for the quarter that ended in Mar. 2024 was -39.24%.

The historical rank and industry rank for KORU Medical Systems's ROE % or its related term are showing as below:

KRMD' s ROE % Range Over the Past 10 Years
Min: -53.18   Med: 0.24   Max: 14.72
Current: -53.15

During the past 13 years, KORU Medical Systems's highest ROE % was 14.72%. The lowest was -53.18%. And the median was 0.24%.

KRMD's ROE % is ranked worse than
78.91% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.15 vs KRMD: -53.15

KORU Medical Systems ROE % Historical Data

The historical data trend for KORU Medical Systems's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems ROE % Chart

KORU Medical Systems Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.58 -5.11 -12.56 -25.54 -53.18

KORU Medical Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.56 -34.49 -19.71 -124.99 -39.24

Competitive Comparison of KORU Medical Systems's ROE %

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KORU Medical Systems's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's ROE % distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's ROE % falls into.



KORU Medical Systems ROE % Calculation

KORU Medical Systems's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-13.741/( (31.326+20.354)/ 2 )
=-13.741/25.84
=-53.18 %

KORU Medical Systems's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-7.744/( (20.354+19.118)/ 2 )
=-7.744/19.736
=-39.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


KORU Medical Systems  (NAS:KRMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-7.744/19.736
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.744 / 32.792)*(32.792 / 27.981)*(27.981 / 19.736)
=Net Margin %*Asset Turnover*Equity Multiplier
=-23.62 %*1.1719*1.4178
=ROA %*Equity Multiplier
=-27.68 %*1.4178
=-39.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-7.744/19.736
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.744 / -7.744) * (-7.744 / -7.844) * (-7.844 / 32.792) * (32.792 / 27.981) * (27.981 / 19.736)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9873 * -23.92 % * 1.1719 * 1.4178
=-39.24 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


KORU Medical Systems ROE % Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


KORU Medical Systems (KORU Medical Systems) Business Description

Traded in Other Exchanges
N/A
Address
100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Executives
Manko Joseph M. Jr. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller officer: Chief Commercial Officer 26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan director C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby officer: President and CEO BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c. officer: Chief Financial Officer C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams officer: Interim CFO 524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case officer: Chief Technology Officer 424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin director 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French director 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew officer: Pres./Chief Commercial Officer 7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher officer: CFO 24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger director 24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103